PMC3808807_01
Temporal changes in eGFR after treatment ( ) and the expected decline in eGFR based on annual decreases of 2 ( ) and 4 ml/min/1.73 m2 ( ). Case 1: 78-year-old woman with moderate CKD stage 3; Case 2: 78-year-old diabetic man with moderate CKD stage 3; Case 3: 70-year-old hypertensive diabetic woman with severe CKD stage 4; Case 4: 81-year-old hypertensive man with CKD stage 4.
cru-0003-0074-g01.jpg
PMC3808807_01_cru-0003-0074-g01.jpg
F1
Clinical characteristics and comorbidities are presented along with treatment regimens and final outcomes with respect to CKD progression (eGFR and/or serum creatinine plus other on-treatment renal chemistry parameters) in table 2 and figure 1 and figure 2.
Temporal changes in serum creatinine. Case 1: 78-year-old woman with moderate CKD stage 3; Case 2: 78-year-old diabetic man with moderate CKD stage 3; Case 3: 70-year-old hypertensive diabetic woman with severe CKD stage 4; Case 4: 81-year-old hypertensive man with CKD stage 4.
cru-0003-0074-g02.jpg
PMC3808807_01_cru-0003-0074-g02.jpg
F2
Clinical characteristics and comorbidities are presented along with treatment regimens and final outcomes with respect to CKD progression (eGFR and/or serum creatinine plus other on-treatment renal chemistry parameters) in table 2 and figure 1 and figure 2.